January 11th 2025
Through this global alliance, PackGene, Weill Cornell Medicine, and GC4K, an Australian non-profit, intend to deliver a custom-tailored gene therapy solution to treat hereditary spastic paraplegia type 56, a particularly rare neurological disease.
The evolution of therapeutic modalities drives the adoption of single-use technologies.
Vertex Pharmaceuticals and CRISPR Therapeutics Amend Agreement for $1.1 Billion
April 21st 2021Vertex and CRISPR have amended their collaboration agreement to include the development, manufacture, and commercialization of CTX001, an investigational CRISPR/Cas9-based gene editing therapy for sickle cell disease and transfusion-dependent beta-thalassemia.
China Approves BeiGene for Commercial Manufacturing at its Biologics Facility
April 8th 2021The China National Medical Products Administration has given the company the green light to begin manufacturing commercial supply of its approved anti-PD-1 antibody, tislelizumab, at its biologics facility in Guangzhou, China.
Harnessing Predictive Simulation to Improve Mixing
April 1st 2021Predictive computational methods are finding wider use in pharmaceutical solid dosage development, particularly in mixing and blending, to improve tech transfer and equipment selection, and speed the acquisition of process understanding.